Korean Journal of Pediatrics 2004;47(7):740-745.
Published online July 15, 2004.
Antithrombin III in the Diagnosis and Treatment of Disseminated Intravascular Coagulation in Premature Infants
Su Jin Cho1, Hye Ryung Choi1, Young Mi Hong1, Kyung Hee Kim2, Keun Lee1, Eun Ae Park1
1Department of Pediatrics, College of Medicine, Ewha Womans University, Seoul, Korea
2Ewha Yeon Hap Pediatric Clinic, Korea
미숙아 파종혈관내응고에서 Antithrombin III 투여의 진단 및 치료적 의의에 대한 연구
조수진1, 최혜령1, 홍영미1, 김경희2, 이근1, 박은애1
1이화여자대학교 의과대학 소아과학교실
2이화연합소아과
Correspondence: 
Eun Ae Park, Email: nea8639@ewha.ac.kr
Abstract
Purpose
: We evaluated the diagnostic implications and therapeutic efficacy of antithrombin III(AT III) in the disseminated intravascular coagulation(DIC) of premature infants.
Methods
: Ninety-two premature infants diagnosed with DIC and treated with AT III from March, 2000 to May, 2003 were retrospectively reviewed. Clinical manifestations, complete blood counts, coagulation tests, and AT III levels were compared between the two groups : definite DIC if clinical signs of DIC and AT III <70% with more than two abnormal laboratory parameters were present, and suspected DIC if not more than two abnormal laboratory parameters were present.
Results
: AT III was given for an average of 3.2 days and no side effects related to the treatment were reported. The AT III levels increased significantly more than four fold with treatment in both groups. The clinical signs and laboratory values improved significantly after treatment.
Conclusion
: AT III level is a sensitive parameter in the diagnosis of DIC in premature infants, and it is useful as a treatment modality since it improves the clinical symptoms and the laboratory parameters without significant side effects.
Key Words: Antithrombin III, Premature infants, Disseminated intravascular coagulation(DIC)


METRICS Graph View
  • 2,374 View
  • 17 Download


Close layer
prev next